The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

Viatris Inc.'s proposed copy of Novo Nordisk A/S’ Wegovy doesn’t infringe a patent on using the once-weekly obesity drug ...

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

If Viatris could sell generic versions of Wegovy and Ozempic, it'd be a major driver of new top-line growth. Sales of Ozempic brought in more than $3 billion for Novo Nordisk in the most recent ...

Viatris is trying to launch generic versions of Novo Nordisk's Ozempic and Wegovy. It should experience an uptick in growth soon, and the stock's valuation is cheap. It's important to keep ...

The office's Patent Trial and Appeal Board denied the requests by Mylan Pharmaceuticals, which is owned by Viatris, to review the validity of the Wegovy and Ozempic patents.

Novo Nordisk's underperformance in recent weeks is attributed to a patent challenge by Viatris over its weight-loss therapy, Wegovy. Read more here.

Read here to know Viatris ... For now, NVO's Wegovy/ Ozempic and Eli Lilly's Mounjaro have been heralded as the next golden goose in the biotech/ pharmaceutical sector, ...

Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, known as Ozempic and Wegovy, according to new research.

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

The weight loss drug Wegovy treated a serious form of liver disease in about two-thirds of patients in a major clinical trial, according to the findings published Wednesday in the New England ...